Kymera Therapeutics

Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

Company plans Phase 1 trial initiations across three novel degrader programs by end of 2021 Initiation of the single ascending dose portion of Phase 1 trial of KT-474 in healthy volunteers anticipated in 1Q 2021 Strong financial position to support pipeline execution with opportunities to